Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: BelgiumFázis nélkül

Benefits of a Renal Rehabilitation Program Adapted to Uremic Patients on Daily Hemodialysis at Low Dialysate Flow Rate.

A legfontosabb adatok

Hol
Brussels (Belgium)A helyszín megnézése

AI-kivonat: kiket keres a vizsgálat

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

A vizsgálat olyan felnőtteket keres, akiknek végstádiumú veseelégtelensége miatt hemodialízisre van szükségük, és nemrég hirtelen egészségi probléma miatt kórházban voltak. A vizsgálat a napi, alacsony dialízisoldat-áramlású hemodialízist vizsgálja rehabilitációs programmal együtt.

Életkor
18 éves vagy idősebb
Nem
Minden nem
A betegség stádiuma
Végstádiumú krónikus vesebetegség, amelyhez hemodialízis kell.
Korábbi kezelés
Nemrég kórházi kezelés hirtelen kialakult egészségi probléma miatt.

A részvétel fő kizáró okai

  • Demencia vagy enyhe kognitív zavar (MMSE < 20/30)
  • Nem kompenzált pszichiátriai betegség vagy viselkedészavar
  • Terhesség
  • A veseműködés helyreállt, így a dialízis abbahagyható
  • Szív- vagy egyéb állapot, amely miatt terheléses vizsgálat nem végezhető, például nem kompenzált szívelégtelenség vagy 200/110 Hgmm feletti vérnyomás

Ez a vizsgálat csak dializált résztvevőket keres. A regiszter mondata, amelyen ez alapul: patient with terminal chronic kidney disease requiring hemodialysis treatment

Gépi kiolvasás: 2026. november 12.

Helyszínek itt: Belgium

  • CHU BrugmannBrussels, BelgiumContact: Joris Vanparys, MDRésztvevőt keres

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

A vizsgálat adatai

Ki végzi
Brugmann University Hospital
Azonosító
NCT07413315
A regiszteradat frissítve
2026. február 17.
Eredeti leírás
The concept of renal rehabilitation has become increasingly important with the increasing age of patients with severe or even terminal chronic kidney disease (CKD). It combines physical exercise and nutritional monitoring programs for patients with terminal CKD who are most often treated with conventional hemodialysis (HD) at a rate of 3 sessions of 4 hours per week.A teljes eredeti leírásKevesebb

The concept of renal rehabilitation has become increasingly important with the increasing age of patients with severe or even terminal chronic kidney disease (CKD). It combines physical exercise and nutritional monitoring programs for patients with terminal CKD who are most often treated with conventional hemodialysis (HD) at a rate of 3 sessions of 4 hours per week.

Sarcopenia is a very common phenomenon in patients with CKD. The prevalence found in recent meta-analyses varies between 25.6 and 28.5% in patients treated with dialysis. It is even higher in patients treated with HD than in patients treated with peritoneal dialysis (PD). Younger and more active patients will more often choose PD. The conventional HD modality preserves residual renal function less well, which is important for better elimination of uremic toxins bound to plasma proteins. Conventional HD requires a higher immobilization time and causes more post-dialysis symptoms, leaving less time for the patient to be physically active.

The phenomenon of sarcopenia is not insignificant. It is associated in dialysis patients with a higher mortality rate (risk x 1.8) and a higher incidence of cardiovascular events (risk x 3.8). The association with higher mortality is well demonstrated for the 2 main components of sarcopenia, namely reduced muscle mass and reduced muscle strength. Sarcopenia also increases the risk of falls and fractures, it decreases the physical performance of patients and their ability to perform activities of daily living. The quality of life of patients is reduced and the probability of social placement is high.

The phenomena of sarcopenia and physical deconditioning are even more problematic in patients in HD after an acute medical problem. The need for rehabilitation is even higher. "Classical" HD treatment can be a burden for these patients, leaving no room for integrating a complete rehabilitation program.

Daily low dialysate flow rate hemodialysis (LDF) is a type of hemodialysis in which patients benefit from more frequent but shorter and hemodynamically better tolerated HD sessions. This new technique potentially presents certain advantages over conventional HD, particularly at the cardiovascular level: better blood pressure control and better reduction of left ventricular hypertrophy. LDF also allows better control of hyperphosphatemia with a reduced need for phosphorus binders. Thanks to more frequent dialysis (5 to 6 sessions per week), inter-dialytic weight gain is often less significant, allowing less aggressive ultrafiltration, with better hemodynamic tolerance, and better post-dialysis recovery. In this perspective, this study aims to examine the interest of integrating HDQ dialysis into a renal rehabilitation program in patients with terminal CKD whose dialysis must continue after an acute event requiring hospitalization. The investigators want to study whether this technique allows the implementation of a more effective rehabilitation program, while maintaining the same dialysis efficiency as with the conventional HD technique. To the investigator's knowledge, no study concerning patients under HDQ has been conducted during their renal rehabilitation phase.

The objectives of the current study are:

* To study the interest of integrating HDQ dialysis into a renal rehabilitation program in patients with terminal CKD. * To study the efficacy and tolerance of HDQ dialysis and the rehabilitation program in these patients.

Bevonási feltételek: patient with terminal chronic kidney disease requiring hemodialysis treatment; patient recently hospitalized for an acute medical event.

Kizáró feltételek: dementia/mild cognitive impairment (MMSE < 20/30); decompensated psychiatric pathology and/or behavioral disorders; severe or poorly tolerated cardiac rhythm disorder; decompensated heart failure; recent stroke or TIA; acute venous thrombosis with or without pulmonary embolism; poorly controlled clinical condition, such as marked anemia, significant electrolyte disturbance, hyperthyroidism, etc; pregnant woman; recovery of renal function allowing interruption of helodialysis sessions; candidate for neurological rehabilitation; patient with recent spinal cord injury; patient with absolute and/or relative contraindication to performing a stress test; severe or symptomatic obstruction to left ventricular ejection; acute myocarditis, pericarditis or endocarditis; acute aortic dissection; high-risk emboligenic intracardiac thrombus; significant stenosis of the common trunk; ventricular aneurysm; supraventricular tachycardia with poorly controlled ventricular rate, acquired high-degree or complete block; obstructive cardiomyopathy with high resting gradient; lack of cooperation from the patient; Blood pressure > 200/110 mmHg.

ClinicalTrials.gov NCT07413315